Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use a “compliant 340B inventory replenishment model,” the company said in a public notice late last week.
Astellas updated the NDC on Cresemba’s 372mg intravenous formulation on Feb. 20, according to a notice posted late last week on the U.S. Health Resources and Services Administration (HRSA) website.
“For purposes of pricing and purchasing from Astellas through the 340B program, Astellas considers the new NDC as if it were the same as the old NDC,” it said. Astellas in late January posted a similar notice regarding an NDC update for Cresemba’s capsule formulation.
Cresemba is indicated to treat rare mold infections that typically affect only people with weakened immune systems. The product’s global sales totaled $363 million between October 2021 and September 2022, according to Astella’s development partner, Switzerland-based Basilea Pharmaceutica.